Tag:

ImmunoGen

Latest Headlines

Latest Headlines

Sanofi dumps an ImmunoGen cancer drug as it scales back in oncology

Sanofi is again trimming its oncology pipeline, walking away from an armed-antibody cancer treatment licensed from ImmunoGen as it reshapes its approach to the field.

ImmunoGen strikes $440M ADC deal with Takeda

ImmunoGen has struck a $440 million antibody-drug conjugate licensing deal with Takeda, moving it a step closer to recovering from the body blow of last year's Phase III flop. The heavily backloaded deal was cheered by investors.

ImmunoGen strikes $440M ADC deal with Takeda

ImmunoGen has struck a $440 million antibody-drug conjugate licensing deal with Takeda, moving it a step closer to recovering from the body blow of last year's Phase III flop. The heavily backloaded deal was cheered by investors, sending ImmunoGen's stock up 21% in premarket trading.

ImmunoGen plummets as its Roche-partnered cancer drug comes up short

ImmunoGen watched its shares fall by 50% when partner Roche revealed disappointing results for the pair's targeted cancer drug, casting doubts on the biotech's technology for creating armed antibodies.

ImmunoGen scuttles lead PhII armed-antibody trial after tracking infection risk

ImmunoGen garnered considerable attention for the tech support role it played on Roche's armed antibody Kadcyla. But an attempt to steer one of its own antibody-drug conjugates through clinical studies ended in disaster today.

ImmunoGen bags ADC deal with Novartis

Antibody-drug conjugate superstar ImmunoGen has signed another agreement to lend its targeted drug technology to Novartis for an undisclosed cancer therapy.

Eli Lilly inks $200M armed antibody pact with ImmunoGen

ImmunoGen says it's struck a $200 million deal to collaborate with Eli Lilly ($LLY) on developing new armed antibodies.

Genentech nabs FDA approval for T-DM1 cancer killer

Roche's Genentech picked up FDA approval for its late-stage breast cancer therapy Kadcyla, formerly T-DM1, which uses antibodies to deliver cancer drugs directly to the offending cells.

Targacept taps Stephen A. Hill to serve as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Roche, ImmunoGen gain speedy review for T-DM1 breast cancer breakthrough

Roche has gained the inside track in the final lap of a long and expensive race to win an FDA approval for the armed antibody T-DM1, a new approach to treating HER2-positive breast cancer that marks a significant advance for patients.